참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 3-Bromopyridine | HCID 12286 | — |
| 반응물 | (R)-1-Boc-3-methylpiperazine | HCID 2756811 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl | HCID 16217985 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | tert-butyl (3R)-3-methyl-4-pyridin-3-ylpiperazine-1-carboxylate | HCID 89555981 | 0% |
반응 단계
diacetoxypalladium (9.34 mg, 0.04 mmol) and RuPhos (0.039 g, 0.08 mmol) were suspended in 1,4 dioxane (5 mL), degassed and stirred at 50 °C for 10 minutes. Then (R)-tert-butyl 3-methylpiperazine-1-carboxylate (0.100 g, 0.50 mmol), 3-bromopyridine (0.040 mL, 0.42 mmol) and cesium carbonate (0.203 g, 0.62 mmol) were added and the reaction mixture was stirred at 100 °C for 16 h. LCMS showed only 5% conversion to desired product. This was part of a screen and Ruphos, sodium tert-butoxide in toluene gave far better conversion so this was abandoned.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-a21d6ec12c02473a98dce7de6b637849 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|
